A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-04-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT00964730
- Locations
- 🇺🇸
Cetero Research - Fargo, Fargo, North Dakota, United States
Azilect + Antidepressant Chart Review
Completed
- Conditions
- Serotonin Syndrome
- Interventions
- Drug: Group AD Anti-PD + AntidepressantDrug: Group R+AD Rasagiline + AntidepressantDrug: Group R Rasagiline
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1500
- Registration Number
- NCT00955604
Safety of New Formulation of Glatiramer Acetate
Phase 3
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT00947752
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 684
- Registration Number
- NCT00936676
- Locations
- 🇺🇸
Teva Investigational Site 7002, Allentown, Pennsylvania, United States
🇺🇸Teva Investigational Site 7020, Boca Raton, Florida, United States
🇺🇸Teva Investigational Site 7016, Farmington, Connecticut, United States
Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Other: Bradykinesia UPDRS Motor Full ExaminationOther: Bradykinesia subscale of UPDRS Motor Examination
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00932581
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Phase 3
Completed
- Conditions
- Non-Hodgkin's LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT00877006
- Locations
- 🇺🇸
Teva Investigational Site 52, Fountain Valley, California, United States
🇺🇸Teva Investigational Site 72, Augusta, Georgia, United States
🇺🇸Teva Investigational Site 48, Chicago, Illinois, United States
A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2009-09-16
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00868361
- Locations
- 🇺🇸
Covance Clinical Pharmacology Inc., Madison, Wisconsin, United States
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00856635
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
Phase 2
Completed
- Conditions
- Seasonal Allergic RhinitisHayfever
- Interventions
- Drug: Beclomethasone dipropionate HFA Nasal AerosolDrug: Placebo
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 487
- Registration Number
- NCT00854360
- Locations
- 🇺🇸
Teva Global Respiratory Research Study Site, Richmond, Virginia, United States
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Phase 2
Completed
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 334
- Registration Number
- NCT00837265
© Copyright 2025. All Rights Reserved by MedPath